Experienced Executive Rina Wolf Well-Positioned to Help Drive Company
SALT LAKE CITY, Aug. 29 /PRNewswire/ -- Axial Biotech, Inc., a company poised to revolutionize spine care through the development of molecular diagnostic and motion preserving technologies, announced today that it has named Rina Wolf as the company's new Vice President of Reimbursement and Regulatory Affairs.
In her new role, Wolf will be responsible for the creation and implementation of reimbursement strategies and policies. As Axial's liaison to the laboratory community, she will continue her active role in matters relating to reimbursement and regulatory initiatives that impact molecular diagnostics.
John Climaco, President and CEO of Axial Biotech, stated, "One of the key components of Axial's future success will be achieving appropriate levels of insurance coverage for our products and Ms. Wolf's vast experience in this area is second to none. In addition, she brings to our company an unparalleled level of understanding of the complex and rapidly evolving regulatory landscape around molecular diagnostics."
In her most recent role as VP of Reimbursement and Regulatory Affairs with RedPath Integrated Pathology, Wolf was responsible for creating and managing all billing polices and activities, patient advocacy programs, and public/private payer coverage and contracting. This included gaining a favorable Coverage Article for PathFinderTG(R) with RedPath's MAC.
Prior to joining RedPath, Wolf was the Director of Reimbursement and Payer Relations for Genomic Health, Inc. where she helped to develop reimbursement strategies and programs that led to positive coverage policies with major third party payers, as well as a favorable local coverage determination from Genomic Health's Part B Medicare Carrier.
Wolf has also worked at Esoterix (now LabCorp) as Vice President of Contracts, and has worked at both Schering Plough and Searle Pharmaceuticals as a hospital and managed care specialty sales representative. She is a former President and board member of the California Clinical Laboratory Association and has been active with both ACLA and the Coalition for 21st Century Medicine. Wolf has a Bachelor of Arts degree from UCLA and a Masters of HealthCare Administration.
"I am extremely excited to serve in this new capacity and for a company that has the potential to do so much to improve the quality of health care," said Wolf. "I believe Axial Biotech will provide the opportunity to assist in the fulfillment of the promise of molecular diagnostics and personalized medicine in the orthopedic spine arena. I am looking forward to putting the knowledge that I have accumulated to work to lessen reimbursement barriers for the innovative molecular diagnostic assays that the company is in the process of developing."
About Axial Biotech
Axial Biotech, Inc. develops molecular diagnostic assays and motion preservation technologies for common spinal diseases and disorders. Axial has developed the first DNA based prognostic test for Adolescent Idiopathic Scoliosis. Axial is accredited by the College of American Pathologists (CAP) and is certified to comply with the Clinical Laboratory Improvement Amendments (CLIA). Founded in 2002, Axial is based in Salt Lake City, Utah.
|SOURCE Axial Biotech, Inc.|
Copyright©2008 PR Newswire.
All rights reserved